Leerink Swann Resumes Orexigen Therapeutics (OREX) at Outperform
Tweet Send to a Friend
Get Alerts OREX Hot Sheet
Price: $6.04 -0.17%
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade OREX Now!
Leerink Swann resumes coverage on Orexigen Therapeutics (NASDAQ: OREX) with a Outperform rating and $10 price target.
The firm said, "Despite recent appreciation, we believe the current stock price still provides an attractive entry point ahead of upcoming catalysts. These include potential additional competitor obesity drug approvals and clinical trial progress and approval of OREX's lead obesity product Contrave."
Our analysis and MEDACorp feedback lead us to believe VVUS's (Nasdq: VVUS) Qnexa will gain approval by its 7/17/12 PDUFA. This would serve as an incremental driver for OREX, in our view. Longer term, KOLs believe Contrave could be approved in 2014 with a competitive profile."
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $7.06 yesterday, with a 52 week range of $1.22-$7.36.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said, "Despite recent appreciation, we believe the current stock price still provides an attractive entry point ahead of upcoming catalysts. These include potential additional competitor obesity drug approvals and clinical trial progress and approval of OREX's lead obesity product Contrave."
Our analysis and MEDACorp feedback lead us to believe VVUS's (Nasdq: VVUS) Qnexa will gain approval by its 7/17/12 PDUFA. This would serve as an incremental driver for OREX, in our view. Longer term, KOLs believe Contrave could be approved in 2014 with a competitive profile."
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $7.06 yesterday, with a 52 week range of $1.22-$7.36.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- BTIG Starts Ambac Financial (AMBC) at Buy, Interesting Play with 'Optionality'
- Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
- Barclays Starts AT&T (T) at Equalweight
Create E-mail Alert Related Categories
Hot New Coverage, New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
